On November 6, 2019 Primmune Therapeutics reported that it will present primate pharmacology data on PRX034 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2019 in National Harbor, MD (Press release, Primmune Therapeutics, NOV 6, 2019, View Source [SID1234550592]). PRX034 is a novel orally bioavailable small molecule toll-like receptor 7 (TLR7) agonist that activates innate immunity by systemically targeting plasmic cytoid dendritic cells in vivo. PRX034 was derived from Primmune’s lead series of novel TLR7 agonists and demonstrates the potential of these compounds to improve response rates and treatment durability of adaptive immune therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There is a very strong rationale for combining agents that activate innate immunity, like PRX034, with drugs that engage adaptive immunity, like checkpoint inhibitors, to potentially address patients who inadequately respond to approved treatments," said James Appleman, Ph.D., Co-founder and Chief Scientific Officer at Primmune Therapeutics. "Our program builds upon historical clinical experience with TLR7 agonists, which we used to identify an ideal pharmacologic profile supporting the notion that long-term systemic dosing with TLR7 agonists best complements adaptive immunity approaches."

"PRX034 meets the initial target product profile criteria that we outlined at the beginning of our discovery campaign and we are in the process of completing the final set of confirmatory studies before entering formal IND enabling GLP non-clinical studies," said Charlie McDermott, Chairman & Chief Executive Officer of Primmune Therapeutics.

Poster presentation details:

Title: Pharmacodynamic response in vitro and in vivo of novel orally administered Toll¬-like Receptor 7 agonists for systemic immunotherapy of cancer
Abstract #: P670
Category: Immune stimulants and immune modulators
Presentation: Saturday, November 9, 2019 by James R. Appleman, Ph.D.